NICE Approves Pharmaxis' Bronchitol® As An Important New Treatment Option For Cystic Fibrosis Patients

NICE Approves Pharmaxis' Bronchitol® As An Important New Treatment Option For Cystic Fibrosis Patients PR Newswire BURNHAM, England, October 26, 2012 BURNHAM, England, October 26, 2012 /PRNewswire/ -- The European headquarters of Australian pharmaceutical company Pharmaxis (ASX: PXS) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a positive recommendation in their Final Appraisal Determination (FAD) for Bronchitol® (mannitol dry powder for inhalation), licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of care. Bronchitol® is the first CF product to have been fully reviewed and received a positive recommendation from NICE. The recommendation provides a new option for CF patients critically requiring new treatments and who have the highest unmet medical need. This includes those patients who cannot use rhDNase (recombinant human deoxyribonuclease) because of ineligibility, intolerance or inadequate response, whose lung function is rapidly declining (forced expiratory volume in 1 second [FEV1] with a decline greater than 2% annually) and for whom other osmotic agents are not considered appropriate.